知镜 Cognispect · 医学文献与研究工作台

Intravenous pulse methylprednisolone versus placebo for ethambutol-induced optic neuropathy (EtON): A double-blind randomized placebo-controlled trial.

Takkar A, Kaur P, Vinay Mahesh K, Tigari B, Muthu V, Soundappan K, Chaurasia S, Singh R, Sukhija J, Singh P, Malhotra S, Lal V.
Ophthalmology · 2026-11-09 · PMID 43003350

文献摘要

Purpose Ethambutol-induced optic neuropathy (EtON) is a dose-dependent adverse drug effect that may cause irreversible visual impairment, with no established therapeutic interventions beyond drug cessation. The study aimed to evaluate the efficacy and safety of high-dose, short-term intravenous methylprednisolone (IVMP) among patients with EtON. Design This was a prospective, double-blind, placebo-controlled, randomized clinical trial (RCT) conducted at a tertiary care center in India (March 2021 to August 2024). Subjects, participants, and/or controls Patients reporting visual loss while receiving ethambutol and diagnosed with EtON using a pre-defined diagnostic criteria were enrolled. Methods, intervention, or testing A total of 100 patients with EtON were randomized (1:1) using block randomization. Participants received either high-dose IVMP (1gram per day for 5 days) or placebo, alongside standard-of-care therapy. Main outcome measures The primary endpoint was two or more lines improvement in best-corrected visual acuity (BCVA) on Snellen's chart (equivalent to at least ten letters on the logMAR) at 6 months. Secondary endpoints included improvement in mean deviation (MD) and visual field index (VFI) on automated perimetry, along with safety, and adjusted treatment effects. Results At 6 months, 36 (72.0%) patients in the IVMP arm versus 23 (46.0%) in the placebo arm achieved an improvement of two or more lines in BCVA (p=0.008). However, the between-group difference in mean final BCVA was not statistically significant (0.54 (0.6) vs 0.61 (0.6), p=0.534). Significant improvement in visual field parameters was noted in IVMP arm: mean MD (-9.40 vs -13.99 (mean difference: 4.59, 95% CI: 1.35-7.83)) and mean VFI (71.27 vs 62.35 (mean difference: 8.92; 95% CI: 0.20-17.65)). Adjusted analysis confirmed improvement in visual outcomes with IVMP (adjusted risk ratio: 1.62; 95% CI: 1.14, 2.29), consistent across subgroups. No serious treatment-related adverse events were observed. Conclusions Short-term high-dose IVMP administration was associated with a greater proportion of BCVA responders and better visual field parameters in patients with EtON. This is the first RCT to evaluate the role of corticosteroids in EtON. The findings are hypothesis-generating and require confirmation in larger trials.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。